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The	 concept	of	 immune-surveillance	highlights	 the	 key	 role	 of	 the	 immune	 system	 in	 detecting	 and	
destroying	transformed	cells,	thereby	preventing	development	of	cancers.	However,	cancer	cells	can	develop	
mechanisms	 to	escape	 immune-mediated	destruction,	 some	of	which	 include;	downregulating	expression	of	
surface	antigens	to	avoid	detection	by	immune	cells,	upregulating	receptors	that	lead	to	immune	cell	exhaustion	





antibody	derived-	 antigen	binding	domain	 coupled	 to	 intracellular	 T-cell	 signalling	domains.	 First	 generation	
CARs	 consist	 of	 intracellular	 CD3z	 signalling	 domain,	 while	 second	 generation	 CARs	 contain	 additional	 co-
stimulatory	domains	such	as,	CD28	or	4-1BB.		
Another	 immunotherapeutic	approach	 involves	blocking	the	activity	of	 immune	check-point	proteins	
that	acts	as	“brakes”	for	the	immune	system	by	sending	inhibitory	signals,	such	as,	Programmed	Death	-1	(PD-
1).	Both	CAR-T	cells	and	PD-1	blockade	therapy	have	generated	clinical	responses	that	are	largely	variable	and	
limited	 to	a	certain	patient	population.	 In	case	of	CAR-T	cells	an	affirmative	effect	 is	 seen	 in	haematological	
malignancies,	but	rarely	in	solid	cancers.	To	increase	the	clinical	efficacy,	a	combination	of	two	approaches	is	
desired.	
Fibroblast	 activation	protein	 is	 an	antigen	expressed	 in	 stromal	 fibroblasts	 as	well	 as	 cancer	 cells	 of	
different	 tumor	 types,	 including	 those	 of	 epithelial	 origin	 and	 mesotheliomas	 such	 as,	 malignant	 pleural	
mesothelioma	(MPM).	We	have	generated	FAP-specific	CAR-T	cells	harbouring	distinct	co-stimulatory	domains.	
These	redirected	T-cells	were	analysed	extensively	 in	vitro	and	then	tested	 in	vivo	 in	combination	with	PD-1	
blockade.	The	 in	vivo	 studies	were	carried	out	 in	a	humanized	mouse	model,	aiming	to	allow	 interactions	of	
redirected	T-cells	with	human	immune	system	components.		
In	 this	 study,	 we	 identified	 a	 particular	 CAR	 with	 a	 mutated	 CD28	 signalling	 domain	 that	 showed	



















Zellen	 tragen	 nach	 Gentransfer	 einen	 synthetischen,	 chimären	 Antigenrezeptor	 (chimeric	 antigen	 receptor	
(CAR),	mit	Hilfe	dessen	die	T-Zellen	tumor-assoziierte	Antigene	(TAA)	erkennen	können.	CARs	bestehen	aus	dem	
Antigen-erkennenden	Teil	eines	Antikörpers	und	intrazellulären	Signaldomänen,	die	zur	T-Zell-aktivierung	nötig	




wirken.	 Therapien	 mit	 Checkpoint	 Blockaden	 haben	 bei	 Patienten	 ein	 klinisches	 Ansprechen	 der	 malignen	
Tumore	 induziert,	 der	 Erfolg	 der	 Therapien	 war	 jedoch	 sehr	 variabel	 und	 limitiert	 auf	 spezifische	
Patientengruppen.	CAR-tragende	T-Zellen	konnten	bis	dato	nur	bei	hämatologischen,	malignen	Erkrankungen	
erfolgreich	 eingesetzt	 werden	 und	 waren	 ineffektiv	 bei	 soliden	 Tumoren.	 Um	 die	 Behandlung	 von	 soliden,	
malignen	 Erkrankungen	 mit	 CAR-tragende	 T-Zellen	 klinisch	 nutzbar	 zu	 machen,	 wird	 die	 Kombination	 mit	
Checkpoint	Inhibitoren	als	therapeutische	Intervention	vorgeschlagen.	





























































genetic	mutations,	 the	 pathogenesis	 of	 cancer	 is	 diverse	 and	 depends	 on	 tissue	 or	 organ	 of	 origin	 and	 the	
molecular	 mechanisms	 involved	 [2].	 Cancers	 are	 highly	 heterogenous,	 which	 means	 they	 consist	 of	












of	 cancer	 which	 are	 the	 underlying	 principles	 reflecting	 the	 complexity	 of	 cancer	 and	 are	 fundamental	 in	
transformation	of	normal	cell	to	become	a	cancer	cell	[10].		
Cancer	 cells	 are	 self-sufficient	 in	 their	 growth,	 resistant	 to	 anti-growth	 signals,	 insensitive	 to	
programmed	cell	death	 (apoptosis),	possess	a	 limitless	 replicative	potential,	 can	stimulate	 formation	of	own	
blood	 vessels	 to	 allow	 nutrient	 supply	 (angiogenesis)	 and	 can	 invade	 local	 tissue	 and	 spread	 to	 other	 sites	

























tumor	progression	was	highlighted	[11,	17].	For	example,	neutralization	of	 IFN-g	 resulted	 in	 increased	tumor	
growth	[18]	and	mice	lacking	IFN-g	responsiveness	were	shown	to	be	more	sensitive	to	tumor	development	than	
wild	type	mice	[19].	Perforin	was	identified	to	have	a	key	role	in	inhibition	of	tumors	especially,	B	cell	lymphomas	
[20,	 21].	 Furthermore,	 a	 series	 of	 publications	 showed	 that	 immune-deficient	mice	 are	more	 susceptible	 to	
spontaneous	tumor	development	than	wild	type	mice	[22-26].	However,	despite	immune-surveillance,	tumors	
still	develop	in	the	presence	of	a	functioning	immune	system.	By	that	time,	it	was	also	known	that	tumors	which	






















The	 elimination	 phase	 is	 the	 same	 mechanism	 as	 described	 in	 the	 theory	 of	 immune-surveillance,	
whereby	 the	 immune-system	 recognize	 transformed	 cells	 and	 eradicate	 them	before	 they	 can	develop	 into	











antigens	 on	 their	 surface.	 As	 this	 process	 advances,	 the	 immune	 system	 exerts	 a	 selective	 pressure,	 and	
susceptible	 tumor	 clones	 are	 eliminated.	 If	 the	 pressure	 exerted	 by	 the	 immune	 system	 fails	 to	 completely	
eliminate	tumor,	then	it	leads	to	development	of	tumor	cell	variants,	which	are	resistant	to	anti-tumor	immune	













early	 rapid	 pro-inflammatory	 response.	 The	 inflammation	 generated	 by	 innate	 immune	 components	
(granulocytes,	macrophages,	monocytes,	mast	cell,	natural	killer	(NK)	cells,	and	dendritic	cells	(DCs))	is	important	










T-cell	 mediated	 immunity	 is	 a	 part	 of	 the	 adaptive	 immune	 response	 which	 consists	 of	 developing	























Figure	2-3.	Components	of	 the	 immune	system.	 The	 innate	 immune	 response	 includes	 secretion	of	 soluble	
factors	such	as	complement	proteins,	and	other	cellular	factors,	including,	dendritic	cells	(DCs),	granulocytes,	
mast	cells,	macrophages	and	natural	killer	(NK)	cells.	Innate	immunity	provides	the	first	line	of	defense	against	
infections	 or	 pathogens	 by	 germ	 line	 encoded	 pattern-recognition	 receptors	 (PRRs)	 and	 other	 cell	 surface	










































peptides	 from	degraded	cytosolic	and	nuclear	proteins	 to	CD8+	T-cells,	 thereby	generating	a	cytotoxic	T-cell	
response.	The	peptides	presented	by	Class	I	molecules	are	usually	8-10	amino	acid	(a.a)	in	length.	Structure	of	





Figure	 2-5.	 Antigen	 processing	 and	 presentation.	 a	 MHC	 class	 I	molecules	 present	 intracellular	 antigenic	
peptides.	 Firstly,	 the	 antigen	 is	 degraded	 by	 proteasome.	 The	 resulting	 peptides	 are	 translocated	 into	
Endoplasmic	Reticulum	(ER)	lumen	via	transporter	associated	with	antigen	presentation	(TAP).		In	the	ER,	MHC	
class	 I	 molecules	 are	 assembled	 by	 non-covalent	 bonding	 of	 alpha	 heavy	 chain	 with	 b2m.	 The	 peptide	 of	
approximately	8-9	a.a.	inserts	itself	into	peptide	binding	groove	of	MHC	class	I,	which	further	stabilizes	the	whole	
















T-cells	and	certain	 IFN-g	 inducible	cells,	such	as	endothelial	cells	during	 inflammatory	responses	[31].	Class	 II	
molecules	 present	 peptides	 to	 CD4+	 helper	 T-cells	 which	 lead	 to	 T-cell	 activation	 and	 cytokine	 production,	
driving	both	antigen	specific	T	and	B	cell	responses.	Class	II	molecules	are	heterodimers	of	two	non-covalently	
α β























































to	 express	 adhesion	 molecules	 CD44	 and	 CD25	 (IL-2	 receptor	 a).	 At	 this	 stage	 the	 cells	 will	 initate	 TCR	
rearrangement	(DN2).	During	the	DN2	stage,	T-cells	loose	CD117	expression	and	are	fully	committed	T-cells.	At	
DN3	stage	(CD4-CD8-CD24+CD25+CD44lowCD117low),	T-cells	are	engaged	 in	rearranging	combinations	 for	 the	b	
chains.	Between	 the	DN3a	 (CD27low)	 and	DN3b	 (CD27high)	phases,	a	very	 important	 checkpoint	occurs,	 the	b	
selection.	 If	no	 functional	β	chain	can	be	synthesized	 from	TCR	re-arrangements,	 the	cell	will	not	be	able	 to	
produce	a	pre-T	receptor	and	will	die	by	apoptosis.	At	 this	stage	TCR	β	re-arrangement	occurs	resulting	 in	a	
unique	β	chain	of	TCR,	and	successful	pairing	with	invariant	surrogate	pre-Tα	and	CD3	chains	results	in	down-	
























































Following	 recognition	 of	 MHC	 bound	 antigenic	 peptide	 by	 TCR,	 the	 T-cell	 and	 APC	 undergo	 actin	






























































complex	 is	 responsible	 for	propagating	 these	 intracellular	 signals.	 Firstly,	 it	 leads	 to	de-phosphorylation	and	
activation	of	the	tyrosine	kinases	FYN	and	Lck	by	CD45.	FYN	and	Lck	phosphorylate	immunoreceptor	tyrosine-
based	activation	motifs	(ITAMs)	on	the	cytosolic	CD3	complex,	which	further	bind	the	ZAP-70	kinase.	Activated	









cell	 response,	 which	 generates	 cytokines	 and	 chemokines	 that	 activate	 neighbouring	 cells	 or	 recruits	 new	
immune	cells	to	the	site	of	infection.	Second	is	the	cytotoxic	CD8+	T-cell	response	which	directly	kills	the	altered	






Helper	 T-cell	 responses	 consist	 of	 subsets;	 T-helper	1	 (Th1),	 T-helper	2	 (Th2),	 T-helper	17	 (Th17),	 T-
helper	9	(Th9),	follicular	helper	(Tfh)	and	regulatory	(Tregs)	T-cells.	









[52].	 Th17	 cells	 upregulate	 transcription	 factor	 RORgT	 and	 secrete	 large	 amounts	 of	 IL-17	 which	 activates	
neutrophils	 [52].	Overall,	 the	differentiation	 into	a	 specific	 T-cell	 subtype	 is	 influenced	by	 the	nature	of	 the	







A	persistent,	unchecked	 immune	response	can	be	harmful	 to	 the	host.	To	prevent	 this,	 the	 immune	
system	produces	regulatory	T-cells	(Tregs),	which	can	curb	an	immune	response	and	keep	inflammation	in	check.	
Tregs	can	be	produced	directly	from	thymic	selection	(natural	Tregs)	or	as	a	result	of	differentiation	in	presence	







Attributed	 to	 their	 capacity	of	 cytolytic	activity,	CD8+	T-cells	 specialize	 in	eradication	of	 intracellular	
pathogens	and	cancer.	When	CD8+	T-cells	recognize	antigen	in	presence	of	IFNa/b	and	IL-12,	they	differentiate	




























co-stimulatory	 receptors.	 Additionally,	 they	 possess	 increased	 proliferative	 potential	 and	 generate	 a	 more	
intense	 and	 rapid	 immune	 response	 upon	 re-infection.	 Memory	 cells	 can	 traffic	 through	 both,	 secondary	










There	are	 two	main	subclasses	of	memory	T-cells;	 central	memory	 (TCM)	and	effector	memory	 (TEM).	
These	cells	differ	phenotypically	 in	terms	of	cell	surface	markers,	 for	example	adhesion	markers	and	homing	




SLO,	 TCM	 cells	 are	 located	 to	 protect	 from	 a	 systemic	 infection	 and	 invade	 the	 peripheral	 tissues	with	 new	
effector	cells	after	stimulation.	In	contrast,	lack	of	CCR7	and	CD62L	restricts	TEM	cells	to	non	lymphoid	tissues.	
The	 trafficking	 location	 and	 high	 cytolytic	 capacity	 of	 TEM	 cells,	 renders	 them	 as	 “first	 responders”	 in	 the	
peripheral	site	during	re-infection	[48].	Thus,	TEM	cells	control	initial	exposure	to	antigen,	providing	TCM	cells	time	
to	 proliferate	 and	produce	new	effectors.	 The	presence	of	 antigen,	 cytokines	 and	 the	 kind	of	 inflammatory	
environment	can	influence	key	transcription	factors	which	decide	fate	of	T-cell	differentiation	into	effector	or	
naïve effector TEM TCM 
CCR7 +++ – +/– +++
CD62L +++ – +/– +++
CD45RO + +++ +++ +
CD45RA +++ – + ++
CD95 +/– +++ ++ +/–
Granzyme B – +++ +/– –
CD25 – + – –
CD127 ++ +/– + +++



















can	be	 recognized	by	NKG2D	 receptor	expressed	on	NK	 cells,	macrophages	and	 some	cytotoxic	 T-cells	 [56].	
Following	 stimulation,	 NK	 cells	 can	 lyse	 tumors	 by	 secreting	 cytolytic	molecules,	 perforin	 and	 granzyme	 or	
through	 apoptosis-inducing	 ligands	 such	 as	 tumor-necrosis	 factor	 (TNF)-related	 apoptosis	 inducing	 ligand	
(TRAIL)	 [57].	 Additionally,	 NK	 cells	 secrete	 IFN-g	 which	 enhances	 apoptosis	 and	 inhibits	 proliferation	 and	
angiogenesis	 in	 tumor	 cells	 [57].	Macrophages	 can	 lyse	 tumor	 cells	 by	 production	 of	 nitric	 oxide	 and	 other	
















production	by	B	 cells.	Antibodies	 targeting	 cancer	 cell-surface	molecules	 can	 inhibit	 key	 signalling	pathways	









express	 pattern	 recognition	 receptor	NKG2D	which	 recognize	 stress	 induced	 genes	 such	 as	MICA	 and	MICB	
expressed	by	tumor	cells.	NK	cells	use	a	combination	of	inhibitory	and	activating	receptors	such	as,	killer	cell	
immunoglobulin	 like	 receptors	 (KIRs)	 to	 detect	 the	 loss	 of	 major	 histocompatibility	 complex	 (MHC)	 class	 I	
expression	on	tumors.	Dendritic	cells	(DCs)	recognize	apoptotic	tumor	cells	through	receptors	CD36	and	avb5	
and	uptake	them	for	phagocytosis.	Macrophages	and	DCs	use	scavenger	receptor	and	CD91	to	ingest	heat-shock	
proteins	 (HSPs)	 containing	 peptides	 released	 from	 dying	 cancer	 cells.	b.	 Adaptive	 immunity	 cells	 recognize	
cancer	 cells	 through	 cross-priming	 by	 DCs.	 DCs	 that	 have	 captured	 dying	 tumor	 cells	 or	 debris,	 migrate	 to	
regional	lymph	nodes	and	present	the	MHC-restricted	tumor	peptides	to	CD4+	and	CD8+	T-cells.	Mature	DCs	co-
express	co-stimulatory	molecules	B7-1	and	B7-2	and	secrete	IL-12	and	IL-18	to	promote	T	helper	1	(TH1)	CD4+	
response	 and	 cytotoxic	 CD8+	 T-cell	 response.	 Activated	 CD4+	 T-cells	 and	 NKT	 cells	 express	 CD40L	 which	
















































































cell	 responses,	 (5)	 inducing	 tolerance	 in	 antigen	 presenting	 cells	 (APCs)	 by	 enhanced	 secretion	 of	 immune-
suppressive	cytokines	such	as	interleukin	(IL)-10	and	indoleamine	2,3-dioxygenase	(IDO),	(6)	inducing	antigen-
































Characteristics	 of	 T-cell	 exhaustion	 are	 continuous	 increase	 in	 T-cell	 dysfunction	 due	 to	 persistent	
exposure	to	antigen,	up-regulation	of	multiple	inhibitory	receptors	(IR),	loss	of	effector	cytokines;	IL-2,	IFN-g	and	
TNF-a,	altered	cell	metabolism	and	a	distinct	transcriptional	profile	[80].	Exhausted	T-cells	express	a	range	of	




















In	 a	 chronic	 infection	model	 of	 LCMV,	 two	major	 subsets	 of	 PD-1+	 T-cells	were	 identified	 based	 on	
intensity	 of	 PD-1	 expression	 and	 transcriptional	 profile	 [86].	 The	 first	 subset	 with	 phenotype	 T-bethiPD-1int,	
showed	limited	proliferation	and	residual	IFN-g	and	TNF-a	secretion.	Second	subset,	identified	with	high	levels	
of	 Eomesodermin	 (Eomes)	 and	 PD-1	 (EomeshiPD-1hi)	 showed	 higher	 Blimp-1	 and	 granzyme	 B	 production.	
Additionally,	co-expression	of	other	inhibitory	receptors	(CD160,	Lag-3,	2B4	and	Tim-3)	in	EomeshiPD-1hi	cells,	











Checkpoint	 inhibition	 is	 a	 new,	 recently	 accepted	 and	 attractive	 option	 as	 a	 single	 therapeutic	 or	 a	
combination	 partner	with	 other	 standard	 therapies	 for	 cancer.	 Blocking	 antibodies	 against	 PD-1,	 PD-L1	 and	
CTLA-4	have	 shown	 clinical	 success	 and	 are	 continuously	 being	put	 to	 test	 in	 further	 clinical	 trials	 [80].	 The	
expression	of	these	inhibitory	receptors	is	not	just	restricted	to	exhausted	cytotoxic	CD8+	T-cells,	but	also	found	
on	T	helper,	Tregs	and	APCs	[80].	Thus,	the	outcome	of	these	therapeutic	antibodies	cannot	be	narrowed	down	








Also	 it	 is	 used	 to	 treat	 Hodgkin`s	 lymphoma	 and	melanoma	 and	most	 recently	 has	 been	 approved	 for	 the	
treatment	 of	micro-satellite	 instable	 cancer	 of	 any	 entity	 [91].	 In	 regards	 to	 clinical	 testing,	Nivolumab	 and	
Pembrolizumab	 have	 been	 used	 in	 malignant	 melanoma	 and	 NSCLC.	 Nivolumab	 showed	 significant	













(2)	 signal	 in	 T-cell	 activation	 are	 provided	 by	 binding	 of	 TCR	 to	MHC	 bound	 antigenic	 peptide	 (1)	 and	 co-


































































clear	 correlation	 between	 the	 IFN-g	 secretion	 and	 clinical	 response	 [115].	 Since	 it	 is	 not	 always	 possible	 to	
regulate	the	quality	and	quantity	of	TILs	that	can	be	isolated,	new	approaches	have	been	developed	involving	















of	 T-cells	 is	performed	 to	generate	 tumour-reactive	T-cells.	 To	generate	a	 recombinant	TCR,	 an	appropriate	









cells	 targeting	 MART-1	 demonstrated	 significant	 tumor	 regression	 [119].	 Because	 the	 recombinant	 TCR	 is	


















[123,	124].	Although	 the	 first	 generation	CARs	 showed	anti-tumour	 responses,	 they	 failed	 to	expand	 in	 vivo	

























through	CAR-T	 cells	 is	 induced.	 Compared	 to	 the	 first	 three	 generations,	 the	 ‘TRUCK’	 T-cells	 provided	more	
advantages	on	affecting	local	suppressive	cells	and	were	able	to	cause	more	anti-tumour	destruction	[121].	
The	 CAR	 constructs	 are	 transfected	 into	 T-cells	 using	 recombinant	 plasmids	 or	 viral	 vectors,	 which	
directs	 specificity	of	 T-cells	 towards	 the	 target	 antigen	 recognized	by	CAR.	 Thus,	 CAR	harbouring	T-cells	 are	
termed	 as	 “redirected”	 T-cells.	 CARs	 have	 also	 been	 constructed	 to	 target	 specific	 peptides	 bound	 to	 HLA	










established	 role	 in	 signalling	 tumor	 cells	 [128-130].	 Furthermore,	 CD19	 is	 not	 shed	 into	 circulation,	 which	









leukemia	 (CLL)	 [144]	 and	 acute	 lymphoblastic	 leukemia	 (ALL)	 [145].	 These	 studies	 focussed	 on	 relapsed,	
chemotherapy	refractory	patients,	and	employed	predominantly	CD28	and	4-1BB	CARs.	Despite	of	variation	in	



















































specific	cytotoxicity,	 regardless	of	heterogeneity.	Even	after	successfully	 reaching	 tumor,	T-cells	can	become	
dysfunctional	due	to	unfavourable	tumor	microenvironment	characterized	by	nutritional	depletion,	acidic	pH,	
oxidative	stress	and	hypoxia;	presence	of	inhibitory	molecules	and	cytokines;	immune	suppressive	cells,	such	as	










in	 the	 tumor	 microenvironment.	 Another	 study	 conducted	 by	 Moon	 and	 colleagues,	 showed	 augmented	





membrane	 receptor	 and	 generally	 contain	 a	mutation	 in	 the	 intracellular	 chain,	 resulting	 in	 an	 absence	 of	
downstream	signal	 transduction	and	subsequent	 loss	of	 function	[157].	In	 this	way,	DNRs	are	mostly	able	 to	
compete	with	their	endogenous	receptors	for	binding	to	target	ligands.	Cherkassky	et	al	showed	that	combining	




Another	 approach	 to	 circumvent	 checkpoint	 inhibition	 is	 by	 generating	 switch	 receptor.	 Switch	
receptors	contain	the	extracellular	portion	of	an	antibody	specific	for	an	inhibitory	receptor,	such	as	PD-1,	fused	
to	an	 intracellular	 signalling	molecule,	 such	as	CD28,	which	 reinforces	 the	effector	 function	of	 the	cell	 [159,	
160].	 The	 resulting	 CAR	 construct	 function	 as	 “dominant	 negative”	 by	 competing	 with	 endogenous	 PD1.	
Additionally,	 it	 provides	 an	 active	 signalling	 through	 the	 cytoplasmic	 domain	 after	 PD-L1	 binding.	 Liu	 et.	 al.	
inserted	the	PD-1-CD28	switch-receptor	into	CAR	vectors	[160].	This	receptor	was	introduced	by	Prosser	and	
colleagues	 [161]	 and	 contains	 the	 extracellular	 domain	 of	 PD-1	 fused	 to	 the	 transmembrane	 and	 signalling	





infiltrating	 tumors	 and	 peripheral	 blood,	 a	 higher	 ex	 vivo	 anti-tumor	 function,	 and	 pronounced	 cytokine	






CAR-T	cells	significantly	 reduced	tumor	growth	and	 increased	migration	of	adoptively	 transferred	human	NK	
cells	into	the	tumor.	These	NK	cells	demonstrated	an	anti-tumor	activity	through	ADCC	and	by	providing	IFN-









Preclinical	 testing	 in	 cancer	 research	 involves	 transplanting	 human	 xenografts	 into	murine	 hosts	 to	














NSG	 mice	 show	 multi-lineage	 hematopoietic	 cell	 engraftment	 after	 transplantation	 of	 human	
hematopoietic	 stem	 cells	 [171].	 One	 method	 is	 to	 transplant	 human	 PBMCs.	 This	 method	 leads	 to	 stable	
engraftment	of	activated	T-cell	populations.	However,	the	engrafted	mice	usually	develop	xenogenic	GvHD	after	




sophisticated	 method	 is	 transplantation	 of	 human	 hematopoietic	 stem	 cells	 (HSCs)	 in	 mice.	 HSCs	 can	 be	















advanced	method	 is	 the	 bone-liver	 thymus	 (BLT)	model.	 In	 this	 approach,	 fetal	 liver	 and	 thymus	 tissue	 are	









humans,	myeloid	 cells	 form	 the	highest	 fraction	 in	blood	 [182].	 Secondly,	 the	 established	adaptive	 immune	
system	is	naïve	and	an	appropriate	antigen-mediated	T-cell	response	is	not	possible	since	human	T-cells	cannot	
































immunological	 control	 of	 cancer.	 A	 humanized	 mouse	 model,	 which	 provide	 in	 part	 a	 human	 immune	

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Humanized	 mice	 provide	 a	 powerful	 tool	 to	 study	 interactions	 between	 human	 immune	 cells	 and	 human	
cancers.	In	this	study,	we	have	compared	two	different	sources	of	hematopoietic	stem	cells	(HSCs);	one	obtained	
from	second	trimester	human	fetal	liver	(HFL)	tissue,	and	the	other	from	granulocyte	colony	stimulating	factor	
(G-CSF)	 mobilized	 adult	 blood	 (also	 termed	 as	 leukapheresis	 harvests),	 for	 generating	 a	 human	 immune	
compartment	in	NOD-scid/gc-/-	(NSG)	mouse	host.	Our	data	indicates	that	stem	cells	from	leukapheresis	harvests	

































obstacle	to	adequate	understanding	of	the	mechanism	and	efficacy	of	anti-cancer	drugs,	 is	the	 limitations	 in	
currently	available	animal	model	systems.		













































Currently,	 humanized	mice	 are	 increasingly	 produced	 by	 engrafting	 human	HSCs	 into	mice	 of	NOD-
scid/gc-/-	[199]	or	Balb/c-Rag1-/-/gc-/-	[200]	strain.	Although,	these	mice	develop	human	B,	T	,NK	cells	as	well	as	
cells	 on	myeloid	 lineage,	 the	overall	 human	 immune	 system	 function	 is	 incomplete	 [201].	 Furthermore,	 the	
engraftment	levels	varies	and	are	dependent	on	several	factors	including,	genetic	background	and	the	age	of	





by-side	 comparison	 of	 the	 frequencies	 of	 reconstituted	 human	 immune	 populations	 following	 intra-hepatic	
neonatal	 transplantation	 in	 NSG	mice	 that	 received	 HSCs	 from	 either	 of	 the	 sources.	 Additionally,	 we	 also	
compared	the	differentiation	phenotype	of	HSCs	derived	 from	the	 two	sources.	Our	data	 indicate	 that	HSCs	
isolated	from	human	fetal	liver	(HFL)	are	less	differentiated	and	provide	better	reconstitution	in	NSG	mice.	Thus,	












tumor	 efficacy	 of	 redirected	 T-cells.	 To	 this	 end,	 we	 first	 were	 interested	 in	 identifying	 a	 good	 source	 of	
hematopoietic	stem	cells	(HSCs)	that	could	provide	a	robust	human	immune	reconstitution	in	humanized	mice.	
Thus,	 we	 produced	 and	 compared	 humanized	 mice	 using	 HSCs	 derived	 from	 human	 fetal	 liver	 (HFL)	 or	
granulocyte	 colony	 stimulating	 factor	 (G-CSF)	 mobilized	 adult	 blood	 (Leukapheresis;	 Leuk).	 Leukapheresis	
harvests	 were	 left	 overs	 from	 cancer	 patients	 that	 were	 initially	 allocated	 autologous	 CD34+	 stem	 cell	
transplantation	but	did	not	need	further	treatment.		




































that	co-expressed	CD38.	Hemaopoietic	stem	cells	 (HSCs)	 isolated	from	Leukapheresis	 (Leuk)	or	Human	Fetal	
Liver	(HFL)	were	stained	for	CD34	and	CD38	markers	and	analyzed	by	flow	cytometry.	A	Representative	gating	
strategy	is	shown.	To	determine	the	purity	of	CD34+	cell	isolation	and	the	frequency	of	CD34+	cells	co-expressing	








Figure	 3-3.	 HFL	 derived	 hematopoietic	 stem	 cells	 (HSCs)	 provide	 better	 human	 immune	 reconstitution	 in	
humanized	 NSG	 mice.	 A	 Gating	 strategy	 from	 one	 representative	 mouse	 is	 shown.	 Blood	 isolated	 from	
humanized	 mice	 was	 stained	 for	 human	 markers	 CD45,	 CD3,	 CD4,	 CD8	 and	 CD19	 and	 acquired	 on	 a	 flow	
cytometer.	For	analysis,	we	first	gated	on	lymphocytes	fraction	based	on	forward	scatter	(FSC-A)	and	sideward	
















































































































































p < 0.001 p < 0.001

















































































































with	 HFL	 CD34+	 HSCs	 showed	 a	 competent	 and	 functional	 human	 immune	 repertoire	 as	 indicated	 by	
proliferation	of	splenocytes	upon	stimulation	with	PHA,	secondary	lymphoid	or	white	pulp	expansion,	secretion	

















but	 primarily	 generating	 B	 cells	 and	DCs	 [201,	 207].	 Another	 study	 using	 adult	 blood	 derived	HSCs	 showed	
engraftment	of	only	B	cells	in	NSG	mice	[204].		





cells	 would	 need	 to	 travel	 to	 the	 liver,	 which	 is	 the	 primary	 site	 for	 haematopoiesis.	 Considering	 that	
haematopoiesis	occurs	during	the	first	few	weeks	of	mouse	postnatal	development,	a	targeted	delivery	directly	









and	 positive	 selection	 in	 human	 thymus	 [181].	 The	 resulting	 T-cells	 acquire	 a	 specificity	 through	 thymic	
education	and	are	capable	of	generating	 response	 to	 immunizations	 in	vivo	 [181,	208].	Our	model	does	not	
include	co-engraftment	of	human	thymus	which	could	have	provided	more	potent	T-cell	responses.	However,	
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Combination	 therapy	 of	 adoptively	 transferred	 redirected	 T-cells	 and	 checkpoint	 inhibitors	 aims	 for	 higher	
response	rates	in	tumors	poorly	responsive	to	immunotherapy	like	malignant	pleural	mesothelioma	(MPM).	So	




























































immune	 therapy	 using	 FAP	 targeted	 redirected	 T-cells	 [215].	We	 developed	 and	 functionally	 tested	 a	 CAR	
recognizing	FAP	(scFv	F19)	composed	of	a	co-stimulatory	CD28	moiety	lacking	the	lck	signal	(D-CD28)	linked	to	









that	 the	humanized	mouse	model,	due	 to	 its	partly	developed	human	 immune	compartment,	 can	provide	a	
better	estimate	of	the	clinical	response	of	FAP-specific	redirected	T-cells	with	PD-1	blockade.		










































of	adoptive	 immunotherapies	 in	cancer.	We	investigated	the	consequences	of	high	or	 low	degree	of	CD3/28	
stimulation	on	the	phenotype	of	T-cells	and	their	ability	 to	get	 transduced	to	express	CARs.	 It	 is	known	that	
immobilization	of	CD3	and	CD28	specific	antibodies	on	a	surface	such	as	beads	(CD3/28	beads)	can	deliver	a	




Figure	 4-1.	 Phenotypic	 profiling	 of	 T-cells	 activated	with	 CD3/28	 beads	 or	 CD3/28	 ab	 and	 comparison	 of	
transduction	 efficacies.	CD3+	 T-cells	 isolated	 from	 buffy	 donors	 are	 incubated	with	 anti-CD3	 and	 anti-CD28	





are	 transduced	 to	 express	 CD28-CD3z	 or	 D-CD28/CD3z	 CARs.	 Left	 Panel	 shows	 representative	 staining	 for	
redirected	T-cells	post	transduction.	CAR	transduced	T-cells	are	detected	by	FACS	using	anti	human	IgG	antibody	
to	stain	for	CAR	receptor;	gated	huIgG+CD8+	(24%)	and	transduction	efficacies	after	CD3/28	beads	or	CD3/28	ab	
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of	 IL-2	 upon	 antigen-specific	 stimulation.	Nonetheless,	 antigen-specific	 IFN-g	 secretion	 remained	 unaffected	
(figure	4-1	C).	These	findings	indicate	possible	early	senescence	attributed	to	increased	CD57+	cells	and	reduced	
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and	 4-1BB-specific,	 as	 indicated	 by	 Venn	 diagram.	 The	 numbers	 in	 each	 intersection	 of	 the	 Venn	 diagram	
represents	the	number	of	pathways	common	for	those	particular	conditions.	Next,	we	enlisted	the	pathways	
that	were	unique	to	D-CD28	specific	co-stimulation	and	chose	relevant	immune	linked	pathways	from	that	list.	

































Figure	 S4-3.	Heatmaps	 showing	 Log2FC	 values	 of	 genes	 relevant	 to	 A	Cell	membrane	 transporters;	 Glucose	




CAR+CD8+	 cells,	 after	 stimulation	with	 FAP:	 CD28/CD3z	 (F19-CD28/CD3z	 over	 T1-CD28/CD3z),	D-CD28/CD3z	





It	 is	known	that	T-cells	undergo	dynamic	changes	 in	their	metabolism	during	an	 immune	response,	and	that	
metabolic	 changes	 can	 decide	 the	 differentiation	 and	 fate	 of	 T-cells	 [221].	 Our	 findings	 indicate	 a	 highly	
proliferating,	actively	metabolizing	and	a	more	terminally	differentiated	cell	 like	biology	of	 redirected	T-cells	




stimulation	 (figure	4-2	C).	 Activation	 and	proliferation	of	 effector	 T-cells	 is	 often	 accompanied	by	 increased	
levels	of	exhaustion	markers	 [219].	We	 found	 that	although	D-CD28/CD3z	 stimulation	 resulted	 in	enhanced	
expression	of	exhaustion	genes,	e.g.	CTLA4,	BTLA,	ENTPD1	(CD39)	and	HAVCR2	(Tim-3),	 it	also	demonstrated	
reduced	expression	of	 pre-apoptotic	 genes	 and	 increased	 expression	of	 anti-apoptotic	 genes	 (figure	 4-2	D).	




the	exact	 relation	between	autophagy	and	apoptosis	 is	 controversial,	 increasing	 research	evidence	 indicates	
that	 autophagy	 can	 promote	 T-cell	 survival	 by	 negatively	 impacting	 cell	 death	 and	 plays	 a	 role	 in	memory	














Figure	 4-3.	 Expression	 of	 immune	 check	 point	 markers	 on	 redirected	 T-cells.	 FAP-specific	 CAR+	 (F19-








































































































































CD8+	 CAR-T	 cells	 demonstrated	 significantly	 higher	 non-specific	 proliferation	 compared	 to	 CD4+	 CAR-T	 cells	








and	 is	 a	 consequence	 of	 the	missing	 lck	 signal	 (figure	 4-4	 C).	 	 Besides,	D-CD28/CD3z	 CAR-T	 cells	 revealed	



































































































































F19-4-1BB/CD3z) 	 or	 control	 CARs	 (T1-CD28/CD3z,	 T1-D-CD28/CD3z,	 T1-4-1BB/CD3z) A	 Proliferation	 was	
compared	by	 culturing	 CAR	 transduced	 cells	 in	 BrdU	 supplemented	medium	and	 stimulating	with	 (+FAP)	 or	
without	antigen	(no	FAP).	Frequency	of	proliferating	cells	was	determined	by	first	gating	on	huIgG+	(CAR+)	cells	
followed	by	further	selecting	BrdU+	cells.	Pooled	data	from	8	buffy	donors	(n=4)	is	shown.	Statistics	is	done	using	
one	 way	 anova	 with	 tukey’s	 post	 test	 for	multiple	 comparison.	B	 Redirected	 T-cells	 were	 co-cultured	 with	
HT1080FAP	tumor	cells	at	specified	Effector/Target	(E:T)	ratios	and	tumor	cell	lysis	was	measured.	Data	from	2	
representative	 donors	 is	 shown	 (n=4).	 P	 value	 is	 calculated	using	unpaired	 t-test	C	 Cytokines	 IFN-g	 and	 IL-2	
quantified	by	ELISA	in	supernatant	from	co-culture	of	CAR-T	cells	with	tumor	cells.	D	Intra-cellular	staining	(ICS)	
to	measure	frequency	of	IFN-g	and	IL-2	producing	CAR-T	cells	in	response	to	antigen-specific	stimulation	or	no	










































































































































































were	 transduced	 to	 express	 FAP-specific	 CARs	 (F19-CD28/CD3z, 	 F19-D-CD28/CD3z,	 F19-4-1BB/CD3z)	 or	
control	 CARs	 (T1-CD28/CD3z,	T1-D-CD28/CD3z,	T1-4-1BB/CD3z).	The	 resulting	 redirected	 T-cells	 (mixture	of	
CAR	 transduced	 and	 un-transduced	 CD4+	 and	 CD8+	 cells)	 were	 incubated	 with	 FAP	 or	 no	 FAP	 in	 BrdU	
supplemented	medium.	To	identify	proliferating	CAR+	cells	of	CD4+	or	CD8+	lineage;	we	first	gated	on	CD4+	cells	
and	CD8+	cells	 individually,	followed	by	gating	on	huIgG+	cells	and	further	selecting	BrdU+	cells.	Figure	shows	














































































































% proliferating CAR-T cells









Figure	 4-5.	 Survival	 of	 redirected	 T-cells	 in	 humanized	 mice.	 A	 Splenocytes	 were	 harvested	 from	 donor	
humanized	NSG	(huNSG)	mice	and	transduced	to	express	FAP-specific	CARs	with	different	co-stimulations	(F19-




quantified	 by	 qPCR.	 Mean	 CAR	 copies	 corresponding	 to	 each	 group	 and	 time	 point	 are	 indicated	 (-)	 and	
mentioned	 (right	 panel).	 Each	 circle	 represents	 one	 qPCR	 replicate	 (~6	 replicates	 per	 mouse).	 Dashed	 line	
indicates	 detection	 threshold.	 	D	 Number	 of	mice	 (Y-axis)	 that	 showed	 positive	 CAR	 copies	 in	 the	 blood	 at	
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Figure	 S4-7.	 The	 allogenecity	 of	 reconstituted	 human	 immune	 compartment	 in	 humanized	mice	 does	 not	









































































































































































































































































































































specific	 (F19)	 or	 control	 (T1)	 CAR-T	 cells	 with	 different	 co-stimulations	 (CD28/CD3z,	 D-CD28/CD3z	 or	 4-
1BB/CD3z)	are	 seeded	on	 recombinant	human	FAP	coated	plates	 (+FAP)	or	alone	and	with	or	without	PD-1	









In	 this	model,	no	 redirected	T-cells	 could	be	measured	 in	 the	peripheral	blood	 (figure	4-7	A	&	 figure	S4-9).	
Persistence	of	redirected	T-cells	could	be	identified	in	the	Tumor	Infiltrating	Lymphocytes	(TILs)	and	peritoneal	
lavage	 (figure	 4-7	 A).	 Interestingly,	 persistence	 was	 significantly	 enhanced	 in	 T-cells	 redirected	 by	 the	 4-
1BB/CD3z	CAR	contrasting	anti-tumor	efficacy.	Nevertheless,	only	 the	number	of	 redirected	T-cell	by	 the	D-
CD28/CD3z	 showed	a	 significant	 inverse	 correlation	with	 tumor	development	 (figure	4-7	B	&	 figure	 S4-10).	
Finally,	 there	was	no	statistically	 significant	difference	 in	 frequency	of	Tregs	 infiltrating	 tumors	between	the	









































































































































































































































































18	 post	 tumor	 injection.	 Mice	 were	 sacrificed	 based	 on	 pre-defined	 endpoints	 and	 the	 experiment	 was	
terminated	at	day	27.	Starting	from	day	2,	mice	received	PD-1	blocking	antibody	every	fourth	day.	C	FAP-specific	
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Figure	4-7.	Persistence	of	 redirected	T-cells	 in	Tumor	 Infiltrating	 lymphocytes	 (TILs)	and	Peritoneal	 Lavage	
(PL).	A	Copies	of	CAR	gene	per	µg	of	DNA	was	quantified	by	qPCR	in	blood,	TILs,	PL	and	spleen	of	harvested	mice	










































































































































































































































































living	 cells	 and	 then	 CD45+	 cells,	 further	 gating	 CD3+	 cells	 and	 next	 CD4+CD127lo	 and	 finally	 gating	 on	
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2	years	even	when	 intensive	multi-modality	 treatment	 is	performed	for	 localized	disease	 [212,	225].	Even	 if	
asbestos	is	banned	in	the	western	world,	there	are	events	leading	to	large	pollution	with	asbestos	exposure	like	
unforeseen	natural	calamities.	In	contrast,	permanent	release	of	asbestos	is	part	of	working	processes	in	the	































considering	 previously	 observed	 survival	 of	 up	 to	 three	 weeks	 in	 NSG	 mice	 [229].	 As	 expected,	 the	 4-
1BB/CD3z CAR	performed	best	with	regards	to	persistence	until	day	44	in	the	peripheral	blood	of	humanized	
mice.	Multiple	reasons	could	be	responsible	for	this	observation.	Humanized	mice	have	low	levels	of	human	










are	 effector	 memory	 or	 effector	 phenotype	 [229].	 When	 comparing	 T-cells	 expressing	 the	 D-
CD28/CD3z, CD28/CD3z	and	4-1BB/CD3z	CAR,	which	had	the	same	phenotype	after	production,	differences	
could	 be	 observed	 regarding	 gene	 expression	 profiles	 induced	 by	 antigen	 stimulation.	 Previously,	 the	
comparison	 of	 the	 CARs	 using	 CD28	 or	 4-1BB	 highlighted	 the	 different	 gene	 expression	 profile	 indicating	
different	 metabolic	 programs	 [232].	 The	 authors	 have	 shown	 that	 CAR-T	 cells	 with	 4-1BB	 co-stimulation	












results.	 PD-L1	 expression	was	 detected	 in	 about	 20-40%	 of	 the	 clinical	 cases	 [234].	 First,	 this	 indicates	 the	
immune	suppressive	potential	of	MPM	via	immune	checkpoints.	Second,	it	gives	a	very	strong	rational	to	use	
checkpoint	inhibitors	blocking	the	PD-1/PD-L1	axis.	In	combination	with	PD-1	blockade	only	T-cells	redirected	




the	 tumor	cells.	 In	 contrast,	 it	was	 shown	 recently	 that	 redirected	T-cells	with	CD28	co-stimulation	 showed	
increased	in	vivo	functionality	in	a	mesothelioma	model	using	immune-compromised	mice	[158].	We	speculate	
that	the	different	results	are,	 in	part,	attributable	to	 interactions	of	the	humanized	 immune	system	and	the	




















signaling	 through	CD28	co-stimulation,	 in	combination	with	PD-1	blockade	 induced	 transient	 tumor	control.	
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efficacy	 and	possible	 clinical	 outcome	of	 FAP-specific	 redirected	 T-cells.	 In	 clinics,	 the	most	 successful	 CARs	
targeting	CD19	antigen	in	B-cell	malignancies	have	employed	4-1BB	or	CD28	co-stimulatory	domains.	These	co-
stimulatory	CARs	have	shown	variable	efficacy	and	persistence	in	a	largely	diverse	patient	population.		
Parallel	 to	 the	 regularly	used	CD28	and	4-1BB	co-stimulatory	domains,	we	 investigated	a	unique	co-
stimulatory	domain,	which	is	a	modification	of	CD28	domain,	generated	by	site	directed	mutagenesis.	Our	 in	
vitro	data	showed	enhanced	anti-tumor	 functionality	of	 redirected	T-cells	 carrying	 the	modified	CD28	endo-
domain	(D-CD28)	CAR,	in	terms	of	antigen-specific	proliferation,	maximum	anti-tumor	efficacy,	cytokine	release	










Firstly,	 we	 could	 show	 that	 irrespective	 of	 the	 type	 of	 co-stimulation,	 redirected	 T-cells	 survive	 in	






where	 the	D-CD28	 CAR	 showed	maximum	 cytotoxicity	 and	 antigen-specific	 IFN-g	 release.	 In	 tumor	 bearing	





protease	that	 is	not	expressed	 in	normal	tissues	and	mostly	expressed	 in	activated	fibroblasts	responding	to	
pathologic	 situations	 that	 involve	 inflammation	 such	 as,	 arthritis,	 wounding,	 fibrosis	 and	 cancer	 [236].	 The	
restricted	and	stable	genetic	expression	of	FAP	makes	it	an	attractive	target	for	anti-cancer	immunotherapies.	
However,	a	previous	study	has	reported	lethal	bone	toxicity	and	cachexia	in	mice	due	to	immune-targeting	of	




progression	 and	 metastasis	 of	 cancer	 and	 the	 extensive	 cross-talk	 between	 tumor	 cells	 and	 stroma	 [238],	
targeting	both	tumor	and	its	micro-environment	could	provide	an	advantage.	FAP	is	an	ideal	candidate	in	this	
situation	since	it	is	expressed	on	tumor	cells	as	well	as	stromal	fibroblasts	of	more	than	90%	of	human	epithelial	































therapies.	At	histological	 level,	apart	 from	FAP,	MPM	cells	showed	the	expression	of	 the	antigens	calretinin,	
thrombomodulin,	mesothelin	and	cytokeratin-5	[248].	Genetic	alterations	in	MPM	include	mutations	in	three	













study	and	CAR-T	cells	were	detected	 in	 the	tumors.	Additionally,	 there	was	a	 transient	elevation	 in	cytokine	
levels,	including	IL-12,	IL-6,	G-CSF,	MCP-1,	IL1Ra,	and	RANTES	in	the	serum	of	mesothelioma	patients.	No	severe	














CAR	T-cells.	However,	 the	 ideal	co-stimulation	may	depend	on	several	 factors,	namely,	antigen	density,	CAR	
stoichiometry,	binding	affinity	of	the	CAR	and	the	immunological	microenvironment	around	tumors	[252].	For	
our	 future	 studies,	 we	 have	 generated	 anti-FAP	 CARs	 with	 different	 binding	 affinities,	 but	 same	 epitope	
specificity,	 and	 harbouring	 either	 of	 these	 co-stimulations,	 namely	 CD28,	 D-CD28	 and	 4-1BB.	 It	 would	 be	
interesting	to	test	the	impact	of	co-stimulation	on	the	threshold	of	CAR-mediated	T-cell	activation.	Furthermore,	
it	will	be	interesting	to	explore	combinations	of	particular	co-stimulation	and	affinity	that	could	be	used	in	case	
of	 tumors	with	 low	antigen	density.	Consequently,	CAR-T	 cells	 can	be	efficiently	used	 to	 target	 tumors	 that	
heavily	downregulate	expression	of	cell	surface	antigens.	Overall,	these	varying	affinities	would	help	to	optimize	
CAR	sensitivity	to	an	individual	tumor	type	before	clinical	application.	































































































Marker	 Fluorochrome	 Company	 Catalogue	no	 Clone	
BrdU	 APC	 eBioscience	 17-5071-42	 Bu20A	
CCR7	 PECF594	 BD	Biosciences	 562381	 150503	
CD127	 PE/Dazzle	594	 Biolegend	 351336	 A019D5	
CD14	 FITC	 BD	Biosciences	 557153	 MSE2	
CD19	 PE/Cy5	 Biolegend	 302210	 HIB19	
CD25	 APC	 eBioscience	 17-0259-42	 BC96	
CD3	 PE/Cy7	 Biolegend	 300420	 UCHT1	
CD34	 APC	 Invitrogen	 CD34-581-05	 581	
CD38	 PE	 Biolegend	 303506	 HIT2	
CD4	 Bv510	 Biolegend	 317444	 OKT4	
CD4	 PB	 Biolegend	 300521	 RPA-T4	
CD45	 PB	 Biolegend	 304029	 HI30	
CD45	 APC	 BD	Biosciences	 555485	 HI30	
CD45RA	 Bv605	 Biolegend	 304134	 HI100	
CD45RO	 Bv785	 Biolegend	 304234	 UCHL1	
CD57	 PB	 Biolegend	 322316	 HCD57	
CD62L	 Bv510	 BD	Biosciences	 563203	 SK11	
CD69	 FITC	 BD	Biosciences	 555530	 FN50	
CD8	 PerCP	 Biolegend	 344708	 SK1	
CD8	 PE	 BD	Biosciences	 561950	 RPA-T8	
CD8	 FITC	 eBioscience	 11-0088-42	 RPA-T8	
FoxP3	 PE	 eBioscience	 12-4776-42	 PCH101	
HLA-DR	 FITC	 Biolegend	 307804	 L243	
HLA-DR	 FITC	 BD	Biosciences	 556643	 G46-6	
IFN-g	 PE/Cy7	 eBioscience	 25-7319-82	 4S.B3	
IgG	 PE	 Southern	Biotech	 2043-09	 2043-09	
IL-2	 APC	 eBioscience	 17-7029-41	 MQ1-17H12	
NkP46	 APC	 BD	Biosciences	 558051	 9E2	
PD-1	 PE/Dazzle	594	 Biolegend	 329940	 EH12.2H7	











Plasmids	with	 CAR	 transgene.	 Binding	 domain	 of	 CAR	 (scFv)	 was	 cloned	 into	 pBullet	 vector.	

















of	 a	 Lκ-leader	 sequence,	 the	 F19	 antibody	 [256]	 derived	 scFv	 binding	 to	
human	 FAP,	 a	 modified	 human	 CH2CH3	 IgG	 domain	 and	 a	 CD28/CD3ζ	
domain.	
F19-D-CD28/CD3z	 pBullet	vector	with	expression	cassette	coding	for	a	fusion	protein	consisting	


























supplemented	with	 150	 μg/ml	 Hygromycin	 B.	 Additionally,	 200	 μg/ml	 G418	was	 added	 to	 the	medium	 for	











binding	 to	 FcγR+	 cells	 [255].	 Additionally,	 the	D-CD28	 is	 a	modification	 of	 the	 CD28	 co-stimulatory	 domain	
(generated	by	site	directed	mutagenesis)	which	 is	devoid	of	 lck	kinase	binding	site,	to	avoid	 IL-2	release	and	
subsequent	persistence	of	 T-reg	 cells	 [217].	 The	 resulting	CAR	 constructs	were	 termed	as,	FAP-specific;	 F19-
CD28/CD3z,	F19-D-CD28/CD3z	or	F19-4-1BB/CD3z	and	NY-ESO-1-specific;	T1-CD28/CD3z,	T1-D-CD28/CD3z	or	
T1-4-1BB/CD3z.		
For	 retroviral	 transduction,	CD3+	or	CD8+	T-cells	were	purified	 from	healthy	buffy	donors	using	CD3	or	CD8	
microbeads,	respectively	and	employing	MACS	technology	(Miltenyi).	Positive	selection	typically	resulted	in	a	≥	
95%	pure	T-cell	population.	The	cells	were	further	activated	with	CD3/CD28	human	T-cell	activator	dynabeads	
at	a	bead	to	cell	 ratio	of	1:5	 in	T-cell	medium	(TCM)	supplemented	with	cytokines;	 IL-2	(200	 IU/ml),	 IL-7	(10	
ng/ml)	and	IL-15	(10	ng/ml)	at	37°C,	5%	CO2.	After	48	hr,	the	beads	were	removed	and	activated	T-cells	were	
resuspended	 in	 TCM	 supplemented	 with	 cytokines.	 Next,	 transduction	 was	 carried	 out	 by	 co-
culturing/overlaying	the	resulting	T-cell	suspension	on	293T	cells	that	were	transiently	producing	high	titers	of	
retrovirus	 particles	 carrying	 the	 genomic	 information	 of	 the	 CAR	 (293T	 cells	 pre-transfected	 overnight	with	













































































2100	 (Agilent,	 Waldbronn,	 Germany).	 Samples	 with	 RNA	 Integrity	 Number	 (RIN)	 ≥	 7	 were	 used	 for	 library	
preparation.	Average	RIN	=	9.6	(n=16).	The	TruSeq	Stranded	mRNA	Sample	Prep	Kit	(Illumina,	CA,	USA)	was	used	
in	library	preparation.	Briefly,	total	RNA	samples	(100ng)	were	poly-A	selected	and	then	reverse-transcribed	into	
double	 stranded	 cDNA	 with	 Actinomycin	 added	 during	 first-strand	 synthesis.	 The	 cDNA	 samples	 were	




























were	 assessed	within	 each	 gene	 set.	 Using	 CAMERA,	we	 reported	 enriched	 pathways	 corresponding	 to	 the	
differentially	expressed	genes.	Pathways	with	FDR	<	0.05	were	selected.	We	further	 focused	our	analysis	on	
pathways	that	were	unique	to	D-CD28	co-stimulation	through	the	CAR	(Log2FC	of	F19-D-CD28/CD3z	over	T1-D-















density	 of	 4	 X	 106	 cells	 per	ml.	 This	was	 followed	 by	 double	 gradient	 centrifugation	 to	 further	 remove	 the	
contaminating	monocytes	 from	 PBMCs.	 For	 double	 gradient	 centrifugation	 “solution-A”	 (per	 50	ml	 -	mixed	
23.13	ml	Percoll	solution	(GE	Healthcare)	with	1.87	ml	10-fold	PBS)	and	“solution-B”	(46%	of	solution-A	in	R10)	













The	 reconstitution	 of	 human	 immune	 system	 components	 in	 the	 peripheral	 blood	 of	 humanized	NSG	mice	












spleen,	 bone	 marrow)	 by	 qPCR.	 	 To	 test	 the	 anti-tumor	 efficacy	 of	 redirected	 T-cells	 in	 humanized	 mice,	
luciferase	expressing	HT1080FAP	tumor	cells	(0.1	X	106	cells	per	mouse)	were	injected	intra-peritoneally	(i.p.).	
Tumor	development	at	day	1	was	measured	by	in	vivo	bioluminescence	imaging	and	based	on	the	tumor	burden,	
mice	were	 equally	 distributed	 in	 groups.	 This	was	 followed	by	 adoptive	 transfer	 of	 redirected	 T-cells	 i.p.	 at	








pseudocolor	map	 representing	 light	 intensity	was	 superimposed	 over	 a	whole-body	 image.	 Throughout	 the	










Spleens	were	mechanically	 disrupted	using	 the	plunger	of	 a	 syringe	 and	 filtered	 through	70µm	cell	 strainer	
followed	by	separation	of	mononuclear	cells	using	density	gradient	centrifugation	employing	ficoll.	Livers	and	





























MPM,	 and	 the	 patient	 had	 not	 to	 be	 candidate	 for	 pleuropneumectomy.	Main	 exclusion	 criteria	 were	 any	





















All	 animal	 experiments	were	 performed	 in	 accordance	with	 the	 Swiss	 federal	 and	 cantonal	 laws	 on	 animal	
protection	KEK-ZH-Nr.	2011-0498,	KEVT	10/2013	and	41/2016).	The	clinical	trial	was	reviewed	and	approved	by	
the	 cantonal	 ethics	 committee	 of	 Zürich,	 Switzerland	 (ethical	 committee	 KEK-ZH-Nr.	 2012-0106,	 registered	
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